Last reviewed · How we verify
Zopapogene imadenovec (Zopa)
Zopapogene imadenovec (Zopa) is a Oncolytic immunotherapy Small molecule drug developed by Precigen, Inc. It is currently FDA-approved for Metastatic melanoma.
Zopapogene imadenovec is an oncolytic adenovirus engineered to express an immunostimulatory transgene that replicates in tumor cells and triggers anti-tumor immune responses.
Zopapogene imadenovec is an oncolytic adenovirus engineered to express an immunostimulatory transgene that replicates in tumor cells and triggers anti-tumor immune responses. Used for Metastatic melanoma.
At a glance
| Generic name | Zopapogene imadenovec (Zopa) |
|---|---|
| Sponsor | Precigen, Inc |
| Drug class | Oncolytic immunotherapy |
| Target | Tumor cells (non-selective replication); immunostimulatory transgene product |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This is a genetically modified adenovirus designed to selectively replicate within cancer cells while expressing a transgene that enhances immune activation. The virus directly lyses tumor cells and releases tumor-associated antigens, while the transgene product stimulates local and systemic anti-tumor immunity. This combination of oncolytic activity and immunostimulation aims to overcome tumor immune evasion.
Approved indications
- Metastatic melanoma
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Flu-like symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zopapogene imadenovec (Zopa) CI brief — competitive landscape report
- Zopapogene imadenovec (Zopa) updates RSS · CI watch RSS
- Precigen, Inc portfolio CI
Frequently asked questions about Zopapogene imadenovec (Zopa)
What is Zopapogene imadenovec (Zopa)?
How does Zopapogene imadenovec (Zopa) work?
What is Zopapogene imadenovec (Zopa) used for?
Who makes Zopapogene imadenovec (Zopa)?
What drug class is Zopapogene imadenovec (Zopa) in?
What development phase is Zopapogene imadenovec (Zopa) in?
What are the side effects of Zopapogene imadenovec (Zopa)?
What does Zopapogene imadenovec (Zopa) target?
Related
- Drug class: All Oncolytic immunotherapy drugs
- Target: All drugs targeting Tumor cells (non-selective replication); immunostimulatory transgene product
- Manufacturer: Precigen, Inc — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic melanoma
- Compare: Zopapogene imadenovec (Zopa) vs similar drugs
- Pricing: Zopapogene imadenovec (Zopa) cost, discount & access